Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
CD134 (OX40) Monoclonal Antibody (ACT35 (ACT-35)), Biotin, eBioscience™
FIGURE: 1 / 2
CD134 (OX40) Antibody (13-1347-42) in Flow
Product Details
13-1347-42
Species Reactivity
Published species
Host/Isotype
Recommended Isotype Control
Class
Type
Clone
Conjugate
Form
Concentration
Purification
Storage buffer
Contains
Storage conditions
Shipping conditions
RRID
Product Specific Information
Description: The ACT35 monoclonal antibody reacts with human CD134, also known as OX-40. A member of the TNF receptor superfamily, CD134/OX-40 is a 50 kDa type I membrane glycoprotein expressed by activated T lymphocytes. The interaction of CD134 with OX-40L has been implicated in T cell-dependent humoral response, regulation of primary T cell expansion, survival of T cells, size of the memory T cell pool and regulation of tolerance in the CD4^+ T cell compartment.
Applications Reported: This ACT35 (ACT-35) antibody has been reported for use in flow cytometric analysis.
Applications Tested: This ACT35 (ACT-35) antibody has been pre-diluted and tested by flow cytometric analysis of stimulated normal human peripheral blood cells. This may be used at 5 µL (0.25 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.
Target Information
OX40 is a protein receptor found on the surface of T cells, a type of white blood cell that plays a crucial role in the immune system. When activated, OX40 promotes the proliferation and survival of T cells, leading to a stronger immune response against cancer cells and infectious agents. OX40 agonists, which are drugs that activate OX40, have shown promising results in preclinical and clinical studies as a potential immunotherapy for cancer. They can enhance the efficacy of other cancer treatments such as chemotherapy and checkpoint inhibitors, and may also have applications in autoimmune diseases and allergies.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Bioinformatics
Protein Aliases: ACT35 antigen; ATC35 antigen; CD134; CD134 antigen; lymphoid activation antigene ACT35; OX40 antigen; OX40 cell surface antigen; OX40 homologue; OX40L receptor; TAX transcriptionally-activated glycoprotein 1 receptor; tax-transcriptionally activated glycoprotein 1 receptor; Tumor necrosis factor receptor superfamily member 4; tumor necrosis factor receptor superfamily, member 4
Gene Aliases: ACT35; CD134; IMD16; OX40; TNFRSF4; TXGP1L
UniProt ID: (Human) P43489
Entrez Gene ID: (Human) 7293
Performance Guarantee
If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*
Learn more
We're here to help
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support